iSpecimen Announces 1-for-20 Reverse Stock Split
12 9월 2024 - 5:30AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”),
an online global marketplace that connects scientists requiring
biospecimens for medical research with a network of healthcare
specimen providers, announced today that it will effect a
reverse stock split of its issued and outstanding shares of common
stock, par value $0.0001 per share, as well as any shares of common
stock held by the Company in treasury, at a ratio of 1-for-20. The
reverse stock split will become effective at 4:30 p.m. Eastern Time
on September 13, 2024, and the Company's common stock will begin
trading on a split-adjusted basis when the market opens on
September 16, 2024. The Company's common stock will continue to
trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol
"ISPC." The new CUSIP number for the Company's common stock
following the reverse stock split will be 45032V207.
At the Company's annual meeting of stockholders
held on July 19, 2024, the stockholders approved a proposal to
amend the Company's Fourth Amended and Restated Certificate of
Incorporation to effect a reverse stock split in the range of
1-for-10 to 1-for-20, with the final ratio to be determined by the
Board of Directors (the “Board”). On August 19, 2024, the Board
approved a 1-for-20 reverse stock split.
When the reverse stock split becomes effective,
every 20 shares of the Company's issued and outstanding common
stock, as well as all shares held by the Company in treasury, will
automatically be combined into one share of common stock, without
any change in the par value per share. In addition, (i) a
proportionate adjustment will be made to the per share exercise
price and the number of shares issuable upon the exercise of all
outstanding stock options and warrants to purchase shares of common
stock, (ii) a proportionate adjustment will also be made in the
number of shares of common stock issuable upon the vesting of
restricted stock units, and (iii) the number of shares reserved for
issuance pursuant to the Company's stock incentive plans will also
be reduced proportionately. Any fraction of a share of common stock
that would be created as a result of the reverse stock split will
be rounded up to the nearest whole share.
The reverse stock split is intended to increase
the per share trading price of the Company's common stock to better
attract certain institutional and other investors and comply with
the minimum bid price requirement for maintaining the listing of
the Company's common stock on Nasdaq.
Broadridge Corporate Issuer Solutions, LLC, the
Company's transfer agent, will act as the exchange agent for the
reverse stock split. Registered stockholders holding pre-split
shares of the common stock electronically in book-entry form are
not required to take any action to receive post-split shares.
Stockholders of record will be receiving information from
Broadridge Corporate Issuer Solutions, LLC about the process for
exchanging their pre-split shares for post-split shares.
About iSpecimeniSpecimen
(Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations
with healthcare providers that have access to patients and
specimens needed for medical discovery. Proprietary, cloud-based
technology enables scientists to intuitively search for specimens
and patients across a federated partner network of hospitals, labs,
biobanks, blood centers and other healthcare organizations. For
more information, please visit www.ispecimen.com.
Forward Looking StatementsThis
press release may contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," “believe," "estimate," "continue" or similar words.
You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain
projections of future results of operations or financial condition
or state other forward-looking information.
Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to the
risk factors contained in the Company's filings with the U.S.
Securities and Exchange Commission, which are available for review
at www.sec.gov. Forward-looking statements speak only as of the
date they are made. New risks and uncertainties arise over time,
and it is not possible for the Company to predict those events or
how they may affect the Company. If a change to the events and
circumstances reflected in the Company's forward-looking statements
occurs, the Company's business, financial condition and operating
results may vary materially from those expressed in the Company's
forward-looking statements.
Readers are cautioned not to put undue reliance
on forward-looking statements, and the Company assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information, please
contact:
Investor ContactKCSA Strategic
CommunicationsPhil Carlson iSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
iSpecimen (NASDAQ:ISPC)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024